To compare outcomes of women with advanced-stage low-grade serous ovarian cancer and high-grade serous ovarian cancer and identify factors associated with survival among patients with advanced-stage low-grade serous ovarian cancer.
A retrospective study of patients diagnosed with grade 1 or 3, advanced-stage (stage IIIC and IV) serous ovarian cancer between 2003 and 2011 was undertaken using the National Cancer Database, a large administrative database. The effect of grade on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model. Among women with low-grade serous ovarian cancer, propensity score matching was used to compare all-cause mortality among similar women who underwent chemotherapy and lymph node dissection and those who did not.
A total of 16,854 (95.7%) patients with high-grade serous ovarian cancer and 755 (4.3%) patients with low-grade serous ovarian cancer were identified. Median overall survival was 40.7 months among high-grade patients and 90.8 months among women with low-grade tumors (P<.001). Among patients with low-grade serous ovarian cancer in the propensity score-matched cohort, the median overall survival was 88.2 months among the 140 patients who received chemotherapy and 95.9 months among the 140 who did not receive chemotherapy (P=.7). Conversely, in the lymph node dissection propensity-matched cohort, median overall survival was 106.5 months among the 202 patients who underwent lymph node dissection and 58 months among the 202 who did not (P<.001).
When compared with high-grade serous ovarian cancer, low-grade serous ovarian cancer is associated with improved survival. In patients with advanced-stage low-grade serous ovarian cancer, lymphadenectomy but not adjuvant chemotherapy was associated with improved survival.
In advanced serous ovarian cancer, low-grade tumors have a better prognosis than high-grade tumors; in low-grade tumors, lymphadenectomy, but not chemotherapy, is associated with improved survival.
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, and the Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, and the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Allison Gockley, MD, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114; email: firstname.lastname@example.org.
Supported by R25CA092203 from the National Cancer Institute at the National Institutes of Health and The Deborah Kelly Center for Outcomes Research, Massachusetts General Hospital.
Financial Disclosure The authors did not report any potential conflicts of interest.
Presented as a poster at the 2016 Society of Gynecologic Oncology Annual Meeting, March 19–22, 2016, San Diego, California.
Each author has indicated that he or she has met the journal's requirements for authorship.